Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
CKJX839D1US04R is a pragmatic, randomized, double-blind, parallel group, placebo-controlled, multicenter, event-driven study evaluating inclisiran sodium 300 mg subcutaneous administered on Day 1, Month 3 (Day 90), and every 6 months thereafter in participants presenting for elective or urgent percutaneous coronary or peripheral endovascular intervention (PCI or PVI). At the time of a successful revascularization procedure or up to 14 days following the procedure, participants will be randomized and administered the first dose of inclisiran or corresponding placebo in a 1:1 fashion, stratified by the type of index arterial revascularization procedure, either coronary (i.e., PCI) or lower extremity (i.e., PV).
The enrollment population will be representative of typical patients in the US with atherosclerotic cardiovascular disease, either coronary artery disease (CAD) or peripheral artery disease (PAD), and the trial endpoints are designed to be scientifically relevant and clinically meaningful to patients, clinicians, and other persons involved in the care of cardiovascular patients. The trial is designed to also understand how inclisiran therapy can be implemented in real-world clinical practice settings.
The expected enrollment of the trial is approximately 6,000 participants, randomized in a 1:1 fashion to receive inclisiran or placebo, within 14 days of successful percutaneous coronary or lower extremity peripheral endovascular intervention for symptomatic atherosclerotic cardiovascular disease (ASCVD).
Inclisiran sodium or corresponding placebo will be administered by s.c. injection to participants presenting for percutaneous coronary or peripheral endovascular intervention, in addition to usual care according to their individual medical history. All participants randomized to the treatment arm will receive inclisiran in addition to usual care per their regular physician direction, and those participants randomized to placebo will receive matching placebo, as well as usual care treatment, according to their treating physician.
Study duration is determined by event accrual consistent with the event-driven design, i.e., when approximately 2380 primary composite events have occurred and at least 50% of participants have at least 36 months of follow-up. Assuming 18 months of recruitment at a uniform rate, the last patients enrolled will have about 27 months of follow-up. Therefore, study duration should be approximately 4 years.
The study is event-driven, and thus, all participants will be treated (or followed in the case of permanent discontinuation of study drug) until the End of Study visit. As such, the planned duration of treatment cannot be stipulated for an individual participant. The estimated maximum treatment period for an individual participant is approximately 45 months, and the mean treatment duration is expected to be approximately 36 months.
Inclusion Criteria:
Exclusion Criteria:
robin.barron-nelson@duke.edu321-946-2747
jen.holt@duke.edu+1 919 824 6334
Alexander City, Alabama 35010, United States
s.forbus.adv@gmail.com256-215-5323
Northridge, California 91325, United States
Torrance, California 90502, United States
Largo, Florida 33777, United States
Safety Harbor, Florida 34695, United States
Elkhart, Indiana 46514, United States
Rochester Hills, Michigan 48307, United States
Flemington, New Jersey 08822, United States
Haddon Heights, New Jersey 08035, United States
Asheville, North Carolina 28803, United States
Charlotte, North Carolina 28204, United States
Raleigh, North Carolina 27617, United States
Lancaster, Pennsylvania 17602, United States
wwade@cardiologypc.com205-780-4330
cabath@theheartcenter.md256-519-8235
kristen.sheehan@emverahealth.com602.854.1583
bmorgan@cargresearch.com1-870-207-3812
bphillips@arcard.org501-227-7596
vguerrero@pacificoaks.com1-949-284-5715
jacob.pineda@cvisd.com1-619-616-2100
rita.trachuk@johnmuirhealth.com1-925-674-2685
bethany.wexler@johnmuirhealth.com1-925-674-2257
tflores@thriveclinicalresearch.org1-626-823-7095
morgan.rcmg@gmail.com1-949-722-7555
mbrown@flourishresearch.com818-280-4220
breanne.silesky@hcahealthcare.com951-314-4907
michael.d.fechter@kp.org1-858-266-6604
dsmall@sdcardiac.com858-244-6800
olga@lundquist.org323-457-1933
mbrown@flourishresearch.com818-280-4220
torantes@fomatmedical.com805-483-1185 ext. 839
mfam@elegantrd.com818-453-6111
dana.dubas@cuanschutz.edu1-857-383-8096
sgondal@clinre.com1-720-772-8040
brenda.garcia@bpthosp.org203-384-4205
danielle.souza@nuvancehealth.org203-739-7600
lrivera@cafconline.com203-246-9994
vklymenko@cafconline.com754-364-8485
delia.johnson@baycare.org727-462-3578
rembishc@cccheart.com727-467-9393 ext. 3117
jsomerstein@pioneerstudies.com305-420-5541
albert@arrowtrials.com386-278-8000
kailyn.herndon@ufhealth.org1-904-244-8232
asocia@firstcoastcardio.com1-904-718-5787
jonest@cccheart.com727-467-9393
dgutierrez@inpatientresearch.com786-502-4303
ssherk@cvinwfl.com505-918-7057
asalvarrey@gchvfl.com1-850-737-0487
hannabishop@charlotteheart.net941-286-7294
adelafieldtcir@gmail.com813-232-0339
donna.patrick@nghs.com678-989-5001
hhaile@ahsmed.com770-407-6369
yining@uic.edu1-312-355-1861
stacey.pahlke@aah.org1-847-723-5279
jlarge@beaconhealthsystem.org574-522-0337
theheartcenterlcka@yahoo.com(219) 884-9180
kristi.mcguire@reidhealth.org1-765-935-8792
cayla.garner@mercyoneiowa.org515-633-3600
madelyn.cheadle@hcahealthcare.com913-253-3069
aapa1451@drvora.com270-691-1827
laurie.hall@graceresearchllc.com318-638-7309
s.dragon@laheart.org985-871-4155
nkhoshkhoo@tulane.edu504-988-9809
ebagley.cvsolutions@gmail.com318-638-7214
ninaparrottlpncrc@monroeresearch.net-318-737-7876
twalther@northernlight.org207-275-3860
wesley.mcclure@medstar.net1-301-877-5583
iluyomade@capitolcardiology.com301-312-0575
srele@adventisthealthcare.com240-826-6167
theresa.hahn@tidalhealth.org1-410-912-6122
lisa.nguyen@jadestonecr.com240-429-4337
lonna.blaske@umhsparrow.org517-364-5115
jamie.prior@mymichigan.org989-631-2469
eveittoma@gmail.com586-275-9285
kayla.walczynski@aspirus.org218-249-6069
haley.messenger@essentiahealth.org218-786-7964
chelsea.morning@javararesearch.com507-216-0972
meshun.briscoe@sterncardio.com901-271-1000
keads@nmhs.net662-377-3000
nkallas@health.missouri.edu573-882-2296
melissa.kelley@commonspirit.org308-381-8636
nicci.thompson@bryanheart.com402-483-3290
jpotter@commonspirit.org402-328-3946
dru.mcmartin@nmhs.org402-354-0350
pauline.sirrell@hitchcock.org603-650-4638
advancedhc2@gmail.com1-908-526-7201
tvogt@hearthousenj.com856-358-8125
abellafiore@ahvi-nj.com908-291-3405
kdowney@hearthousenj.com856-546-3003 ext. 3262
jmwhite@atlanticare.org1-609-404-7654
smanga@hearthousenj.com856-582-2000 ext. 5281
ssalazar2@phs.org1-505-563-2716
sshah@capitalcardiology.com513-888-1831
tjimenezknight@chsbuffalo.org716-837-2400
jupadhyay@trinitymedicalwny.org716-305-0139
chivelle.mendoza@mountsinai.org1-212-241-7052
muskaan.ochani@nuvancehealth.org845-473-1188
chrgarcia@rumcsi.org1-718-818-2707
cidney.schultz@nychhc.org1-718-918-6212
olivia.lim@hcahealthcare.com828-412-9146
tscaldwell@novanthealth.org704-264-1401
eghaly1@gmail.com201-788-1372
shannon.casey@javararesearch.com1-312-363-8017
heather.mcghee@conehealth.com1-336-832-3799
lisa.wilkerson@advocatehealth.org1-336-885-6168
erin.campo@duke.edu(919) 668-0927
frank.benedetti@duke.edu919-684-3381
jweaver@novanthealth.org1-336-718-6087
barbara.rambaud@aultman.com330-454-8076
khubbard3@mercy.com937-523-9545
abeer.abu-saif@promedica.org1-419-842-3000
cgriffin2@genesishcs.org740-455-7640
rburgan@okheart.com405-628-6865
kyle.mcfadden@sluhn.org1-989-907-4187
asingh@care-research.com717-963-8389
jnewell3@wellspan.org717-262-4697
annmarie.blair@pennmedicine.upenn.edu
mary.alderfer@towerhealth.org610-375-6565
smyers22@wellspan.org1-717-851-3713
sonya.bair@anmed.org1-864-512-8551
aodegard@regionalhealth.org1-605-755-4326
nakia.proge@sterncardio.com901-271-4164
tammy.dicken@balladhealth.org1-423-262-4473
pgibbons@researchjackson.com(731)423-8200
fbruton@jacksonclinic.com1-731-660-8444
michael.brown@hcahealthcare.com1-615-426-9609
alexandraemuniz@gmail.com(806) 355-0558
snguyen@amarilloheart.com806-463-2153
laura.voltz@hcahealthcare.com512-206-3603
syed.zaidi@vitalheartandvein.com1-281-572-0078
fielicia.stowe@tcrinstitute.com832-644-5372
azeez.lawal@sitebridgeresearch.com1-936-249-6489
c.medina@dhrhealth.com1-956-362-2398
teresa.shipwash@hcahealthcare.com512-341-3959
leticia.janak@hcahealthcare.com512-216-6502
dburns@houstonheartcenter.com281-351-4911
emartinresearch@gmail.com832-364-0851
heather.freeman@tpmgpc.com757-232-8836
elizabeth.garrett@hcahealthcare.com804-548-5296
lpeterso@valleyhealthlink.com540-536-4399
fawna.white@multicare.org253-697-4192
trina.wesner@multicare.org253-403-7449
katherine.guilliams@emplifyhealth.org1-920-617-2060